Dollar Steady as Markets Await U.S. Inflation Data 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
Oil Prices Slide as OPEC, IEA Cut 2026 Demand Forecasts 
Australia Housing Crisis Deepens as Worker Shortages Delay Homebuilding 
Add as a preferred source on Google
Lotte Biologics is allocating fresh investments in its own home ground to build three new production plants. The leading pharma company is spending $3 billion for the new facilities that will be constructed in South Korea.
Lotte Biologics is aiming to complete the new factories by the year 2030, and the plan is to build a bio-industrial complex where it will house the three plants. The company is expecting a production capacity of 360,000 liters of anti-body medicines per year in Korea.
As per Pulse News, Lotte Biologic’s chief executive officer, Lee Won Jik, revealed the company’s mid and long-term plan when he attended the J.P. Morgan Healthcare Conference in San Francisco. At that time, he said that they would bolster their business competitiveness to become a major competitor in the contract development and manufacturing organization (CDMO) market. The company’s strategy to achieve this is to acquire assets and build new facilities.
To set its plan in motion, the firm will start the construction of its first plant in the Lotte Bio Campus production complex within the second half of this year. This first factory is set to operate for commercial production by 2027. As for the entire complex, it is expected to be completed in 2034.
Lotte Biologics planned this new investment after completing its acquisition of Bristol Myers Squibb’s manufacturing plant in Syracuse, New York. It purchased the facility for $160 million earlier this month as part of its strategy to expand overseas.
“Each plant will require approximately $1 billion in investment for a total of $3 billion invested by 2030,” Lee said during the presentation. The three plants will each have a 120,000-liter capacity, for a combined 360,000 liters.” Korea Joongang Daily quoted Lotte Biologics’ CEO as saying during the conference with regards to its latest investment in South Korea.
He added, “While the locations have not been announced, the bio company plans to start the construction of the first plant in the second half of this year. The first plant is set to start commercial manufacturing in 2027 after completing the facility in the second half of 2025. It aims to run all of three factories by 2034 and generate $3 billion in sales annually with a profit margin of 35 percent.”
